Liver Transplantation and Uveal Malignant Melanoma

Not Applicable

Completed

• Conditions: Uveal Malignant Melanoma
• Interventions: Procedure: Liver transplantation

• Registration Number: NCT01311466
• Lead Sponsor: Oslo University Hospital

Brief Summary

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01
• Study First Submitted: 2011-03-07
• Study First Submitted QC: 2011-03-07
• Study First Posted: 2011-03-09
• Primary Completion: 2015-10
• Study Completion: 2015-10
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-20
• Last Update Posted: 2017-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Uveal malignant melanoma
• Liver metastases
• ECOG 0-1

Exclusion Criteria

• Extra hepatic disease
• Previous other malignancy
• Previous organ transplantation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Liver transplantation	Liver transplantation	The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital

Primary Outcome Measures

Name	Time	Method
Over all survival	1 year	Patient survival after livertransplantation

Trial Locations

Locations (1)

Oslo University Hospital; 🇳🇴 Oslo, Norway